• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Rabbit anti-Human POMGNT1 Polyclonal Antibody, FITC conjugated

The antibody against POMGNT1 was raised in rabbit using the Recombinant Human Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 protein (59-300AA) as the immunogen. This antibody exists as a fitc conjugated isotype IgG, purified by protein G with a purity greater than 95%.

ADC-24019A

The antibody against POMGNT1 was raised in rabbit using the Recombinant Human Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 protein (59-300AA) as the immunogen. This antibody exists as a fitc conjugated isotype IgG, purified by protein G with a purity greater than 95%.

$299.00

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ADC-24019A ClonalityPolyclonal
Host SpeciesRabbitTarget NamePOMGNT1
FormLiquidSpecies ReactivityHuman
IsotypeIgGStorage Buffer0.01M PBS, 0.03% Proclin 300; Constituents: 50% Glycerol, PH 7.4
Purification Method>95%, Protein G purifiedConjugateFITC conjugated
StorageUpon receipt

Immunogen Information


Immunogen DescriptionRecombinant Human Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 protein (59-300AA)Target SpeciesHuman
Immunogen SequenceComplete sequences for the immunogen, target protein, and peptides are available upon request.Uniprot IDQ8WZA1
Background Information
  • Uniprot Id

    Q8WZA1

  • Target Species

    Human

  • Target Name

    POMGNT1

  • Target Full Name

    Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1

  • Target Function

    Participates in O-mannosyl glycosylation by catalyzing the addition of N-acetylglucosamine to O-linked mannose on glycoproteins. Catalyzes the synthesis of the GlcNAc(beta1-2)Man(alpha1-)O-Ser/Thr moiety on alpha-dystroglycan and other O-mannosylated proteins, providing the necessary basis for the addition of further carbohydrate moieties. Is specific for alpha linked terminal mannose and does not have MGAT3, MGAT4, MGAT5, MGAT7 or MGAT8 activity.

  • Target Involvement

    Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3 (MDDGA3); Muscular dystrophy-dystroglycanopathy congenital with mental retardation B3 (MDDGB3); Muscular dystrophy-dystroglycanopathy limb-girdle C3 (MDDGC3); Retinitis pigmentosa 76 (RP76)

  • Target Subcellular Location

    Golgi apparatus membrane; Single-pass type II membrane protein.

  • Target Protein Families

    Glycosyltransferase 13 family

  • Target Tissue Specificity

    Constitutively expressed. An additional weaker band is also detected in spinal cord, lymph node, and trachea. Expressed especially in astrocytes. Also expressed in immature and mature neurons.

  • Target Synonyms

    2-N-acetylglucosaminyltransferase 1; 2-N-acetylglucosaminyltransferase I.2; GnT I.2; GnTI.2; MEB; MGAT 1.2; MGAT1.2; O linked mannose beta1 2 N acetylglucosaminyltransferase; PMGT1_HUMAN; POMGNT 1; POMGnT1; Protein O linked mannose beta 1 2 N acetylglucosaminyltransferase 1; Protein O linked mannose beta1 2 N acetylglucosaminyltransferase; Protein O-linked-mannose beta-1; UDP GlcNAc; UDP GlcNAc:alpha D mannoside beta 1 2 N acetylglucosaminyltransferase I.2; UDP-GlcNAc:alpha-D-mannoside beta-1

  • Target Background

    This gene encodes a type II transmembrane protein that resides in the Golgi apparatus. It participates in O-mannosyl glycosylation and is specific for alpha linked terminal mannose. Mutations in this gene may be associated with muscle-eye-brain disease and several congenital muscular dystrophies. Alternatively spliced transcript variants that encode different protein isoforms have been described.

Inquire Rabbit anti-Human POMGNT1 Polyclonal Antibody, FITC conjugated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification